ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
알칼리스트(릴로나셉트) 시장 규모는 향후 몇 년간 강한 성장을 보일 것으로 예상됩니다. 예측 기간 동안의 성장은 주사 가능한 생물학적 제제의 수요 증가, 의료비 지출 증가, 전 세계 환자 인구 증가, 염증성 질환 치료에 대한 수요 증가, 개인 맞춤형 의약품에 대한 수요 증가에 기인할 수 있습니다. 예측 기간 동안의 주요 동향으로는 자가 면역 질환에 대한 생물학적 치료법의 발전, 제약 회사 간의 협력, 정밀 의학 및 표적 치료법의 발전, 기술 발전, 의약품 전달 시스템의 혁신 등이 있습니다.
맞춤형 의약품에 대한 수요가 증가함에 따라 알칼리스트(릴로나셉트) 시장의 성장이 촉진될 것으로 예상됩니다. 맞춤형 의학은 유전, 환경, 생활 방식 등 개인의 특성에 맞게 치료 및 의료 결정을 맞춤화합니다. 맞춤형 의학은 치료 효과를 개선하고, 부작용을 줄이며, 질병 진행 및 의약품 반응의 개인별 차이를 해결할 수 있는 잠재력이 있어 그 수요가 증가하고 있습니다. 개인 맞춤형 의학이 보편화됨에 따라 희귀하고 유전적으로 촉진되는 질환을 식별할 수 있는 인식이 높아지고 진단 도구가 개선되어 Arcalyst로 치료할 수 있는 질환의 진단이 증가하고 있습니다. 예를 들어, 2024년 2월, 개인 맞춤형 의학 연합(PMC)은 FDA가 2023년에 희귀 질환 환자를 위한 16개의 새로운 개인 맞춤형 치료법을 승인했다고 보고했습니다. 이는 2022년의 6개에 비해 크게 증가한 수치입니다. 또한, 2023년 2월 PMC는 2022년에 FDA가 12개의 새로운 개인 맞춤형 의약품을 승인했다고 보고했으며, 이는 개인 맞춤형 의약품이 전체 신약 승인 건수의 4분의 1 이상을 차지한 8년 연속 기록입니다. 따라서 개인 맞춤형 의약품에 대한 수요가 증가하면서 알칼리스트(릴로나셉트) 시장의 성장이 촉진되고 있습니다.
알칼리스트(릴로나셉트) 시장의 주요 동향은 기술 통합을 강화하고 시장 도달 범위를 확대하기 위해 알칼리스트를 개발 및 상용화하기 위한 전략적 파트너십 접근 방식을 채택하는 것입니다. 전략적 파트너십을 통해 기업들은 서로의 강점과 자원을 활용하여 상호 성공을 달성할 수 있습니다. 예를 들어, 2022년 2월, 버뮤다에 본사를 둔 바이오 제약 회사인 Kiniksa Pharmaceuticals Ltd.는 중국에 본사를 둔 제약 회사인 Huadong Medicine Co. Ltd.와 아시아태평양 지역에서 Arcalyst 및 mavrilimumab을 개발 및 상용화하기 위해 파트너십을 체결했습니다. 이 계약에 따라 Kiniksa는 2,200만 달러의 선급금을 받고, 개발, 규제 승인 및 판매에 따른 단계별 지급금을 통해 최대 6억 4,000만 달러를 벌 수 있게 되었습니다. Huadong Medicine은 중국, 한국, 호주 및 일본을 제외한 18개 국가에서 Arcalyst의 개발 및 상용화에 대한 독점권을 보유하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 바이오의약품 시장에서의 제품 특성
분자 유형
투여경로(ROA)
작용기전(MOA)
안전성과 유효성
제4장 시장 동향과 전략
제5장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염, 경기 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제6장 세계의 성장 분석과 전략 분석 프레임워크
세계의 알칼리스트(릴로나셉트) : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 알칼리스트(릴로나셉트) 시장 : 성장률 분석
세계의 알칼리스트(릴로나셉트) 시장 실적 : 규모와 성장(2019-2024년)
세계의 알칼리스트(릴로나셉트) 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 알칼리스트(릴로나셉트) : 전체 시장 규모(TAM)
제7장 세계 시장의 가격 분석과 예측
제8장 시장 세분화
세계의 알칼리스트(릴로나셉트) 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
동결 건조
액체
세계의 알칼리스트(릴로나셉트) 시장 : 적응증별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
크리오피린 관련 주기성 증후군(CAPS)
인터루킨-1 수용체 길항제 결핍증(DIRA)
기타
세계의 알칼리스트(릴로나셉트) 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원 약국
소매 약국
온라인 약국
세계의 알칼리스트(릴로나셉트) 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
성인 환자
소아 환자
제9장 임상적응증 세계 시장 역학
약제의 부작용
임상적응증의 발병률과 유병률
제10장 지역별, 국가별 분석
세계의 알칼리스트(릴로나셉트) 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 알칼리스트(릴로나셉트) 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 한국 시장
제17장 서유럽 시장
제18장 영국 시장
제19장 독일 시장
제20장 프랑스 시장
제21장 동유럽 시장
제22장 북미 시장
제23장 미국 시장
제24장 캐나다 시장
제25장 남미 시장
제26장 중동 시장
제27장 아프리카 시장
제28장 경쟁 구도와 기업 프로파일
알칼리스트(릴로나셉트) 시장 : 경쟁 구도
알칼리스트(릴로나셉트) 시장 : 기업 프로파일
Regeneron Pharmaceuticals Inc.
Kiniksa Pharmaceuticals Ltd.
제29장 세계 시장 : 파이프라인 분석
제30장 세계 시장 경쟁 벤치마킹과 대시보드
제31장 주요 인수합병(M&A)
제32장 최근 시장 동향
제33장 시장의 잠재력이 높은 국가, 전략
알칼리스트(릴로나셉트) 시장(2029년) : 새로운 기회를 제공하는 국가
알칼리스트(릴로나셉트) 시장(2029년) : 새로운 기회를 제공하는 부문
알칼리스트(릴로나셉트) 시장(2029년) : 성장 전략
시장 동향에 의한 전략
경쟁 전략
제34장 부록
HBR
영문 목차
영문목차
Arcalyst (rilonacept) is a prescription medication classified as an interleukin-1 (IL-1) blocker. It is used to treat inflammatory conditions caused by the overproduction of interleukin-1, a protein that plays a key role in the body's inflammatory response. Rilonacept works by binding to interleukin-1 alpha and beta, preventing their interaction with specific receptors, thus reducing inflammation and alleviating symptoms related to these conditions.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary formulations of arcalyst (rilonacept) include lyophilized and liquid forms. The lyophilized version is a freeze-dried formulation designed for reconstitution prior to administration. Arcalyst is indicated for conditions such as cryopyrin-associated periodic syndromes (CAPS), deficiency of interleukin-1 receptor antagonist (DIRA), and other indications. It is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is used by both adult and pediatric patients.
The arcalyst (rilonacept) market research report is one of a series of new reports from The Business Research Company that provides arcalyst (rilonacept) market statistics, including arcalyst (rilonacept) industry global market size, regional shares, competitors with a arcalyst (rilonacept) market share, detailed arcalyst (rilonacept) market segments, market trends and opportunities, and any further data you may need to thrive in the arcalyst (rilonacept) industry. This arcalyst (rilonacept) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The arcalyst (rilonacept) market size is expected to see strong growth in the next few years. It will grow to $311.7 million in 2029 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to growing demand for injectable biologics, rise in healthcare expenditure, increasing global patient population, rising demand for treatments for inflammatory diseases, rise in demand for personalized medicine. Major trends in the forecast period include advancements in biologic therapies for autoimmune conditions, collaborations between pharmaceutical companies, advances in precision medicine and targeted therapies, technological advancements, innovations in drug delivery systems.
The growing demand for personalized medicines is expected to drive the growth of the arcalyst (rilonacept) market going forward. Personalized medicine tailors treatment and healthcare decisions to an individual's characteristics, including genetics, environment, and lifestyle. The demand for personalized medicine is rising due to its potential to improve treatment effectiveness, reduce adverse effects, and address individual variability in disease progression and drug response. As personalized medicine becomes more common, there is greater awareness and better diagnostic tools to identify rare, genetically driven conditions, which results in an increase in diagnoses that Arcalyst can treat. For instance, in February 2024, the Personalized Medicine Coalition (PMC) reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, compared to just 6 in 2022. Additionally, in February 2023, PMC reported that 12 new personalized medicines were approved by the FDA in 2022, marking the eighth consecutive year where personalized medicines comprised at least a quarter of all new drug approvals. Therefore, the growing demand for personalized medicines is driving the growth of the arcalyst (rilonacept) market.
A key trend in the arcalyst (rilonacept) market is adopting a strategic partnership approach to develop and commercialize Arcalyst with enhanced technology integration and to expand market reach. Strategic partnerships enable companies to leverage each other's strengths and resources to achieve mutual success. For instance, in February 2022, Kiniksa Pharmaceuticals Ltd., a Bermuda-based biopharmaceutical company, partnered with Huadong Medicine Co. Ltd., a China-based pharmaceutical company, to develop and commercialize Arcalyst and mavrilimumab in the Asia-Pacific region. Under this agreement, Kiniksa received an upfront payment of $22 million and could earn up to $640 million through milestone payments based on development, regulatory approvals, and sales. Huadong Medicine holds exclusive rights for the development and commercialization of Arcalyst in Greater China, South Korea, Australia, and 18 other countries, excluding Japan.
In August 2023, Fairmount Funds Management LLC, a South Philadelphia-based investment firm, acquired a stake in Kiniksa Pharmaceuticals for an undisclosed amount. This strategic move is part of Fairmount's broader investment strategy aimed at long-term value generation within the biotechnology sector. Kiniksa Pharmaceuticals is the manufacturer of Arcalyst (rilonacept).
Major players operating in the arcalyst (rilonacept) market are Regeneron Pharmaceuticals Inc., Kiniksa Pharmaceuticals Ltd.
North America was the largest region in the arcalyst (rilonacept) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in arcalyst (rilonacept) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the arcalyst (rilonacept) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The arcalyst (rilonacept) market consists of monoclonal antibodies, anti-inflammatory drugs, rare disease drugs and other related products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Arcalyst (rilonacept) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on arcalyst (rilonacept) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for arcalyst (rilonacept) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The arcalyst (rilonacept) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Lyophilized; Liquid
2) By Indication: Cryopyrin-Associated Periodic Syndromes (CAPS); Deficiency Of Interleukin-1 Receptor Antagonist (DIRA); Other Indications
3) By Distribution Channels: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By End User: Adult Patients; Pediatric Patients
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Arcalyst (Rilonacept) Market Characteristics
3. Arcalyst (Rilonacept) Market Biologic Drug Characteristics
3.1. Molecule Type
3.2. Route Of Administration (ROA)
3.3. Mechanism Of Action (MOA)
3.4. Safety And Efficacy
4. Arcalyst (Rilonacept) Market Trends And Strategies
5. Arcalyst (Rilonacept) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
6. Global Arcalyst (Rilonacept) Growth Analysis And Strategic Analysis Framework
6.1. Global Arcalyst (Rilonacept) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.2. Analysis Of End Use Industries
6.3. Global Arcalyst (Rilonacept) Market Growth Rate Analysis
6.4. Global Arcalyst (Rilonacept) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
6.5. Global Arcalyst (Rilonacept) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
6.6. Global Arcalyst (Rilonacept) Total Addressable Market (TAM)
7. Global Arcalyst (Rilonacept) Market Pricing Analysis & Forecasts
8. Arcalyst (Rilonacept) Market Segmentation
8.1. Global Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Lyophilized
Liquid
8.2. Global Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cryopyrin-Associated Periodic Syndromes (CAPS)
Deficiency Of Interleukin-1 Receptor Antagonist (DIRA)
Other Indications
8.3. Global Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
8.4. Global Arcalyst (Rilonacept) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Adult Patients
Pediatric Patients
9. Global Arcalyst (Rilonacept) Market Epidemiology Of Clinical Indications
9.1. Drug Side Effects
9.2. Incidence And Prevalence of Clinical Indications
10. Arcalyst (Rilonacept) Market Regional And Country Analysis
10.1. Global Arcalyst (Rilonacept) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. Global Arcalyst (Rilonacept) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Asia-Pacific Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Asia-Pacific Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. China Arcalyst (Rilonacept) Market
12.1. China Arcalyst (Rilonacept) Market Overview
12.2. China Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
12.3. China Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
12.4. China Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
13. India Arcalyst (Rilonacept) Market
13.1. India Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. India Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. India Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. Japan Arcalyst (Rilonacept) Market
14.1. Japan Arcalyst (Rilonacept) Market Overview
14.2. Japan Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. Japan Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. Japan Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Australia Arcalyst (Rilonacept) Market
15.1. Australia Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.2. Australia Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Australia Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. South Korea Arcalyst (Rilonacept) Market
16.1. South Korea Arcalyst (Rilonacept) Market Overview
16.2. South Korea Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. South Korea Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.4. South Korea Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Western Europe Arcalyst (Rilonacept) Market
17.1. Western Europe Arcalyst (Rilonacept) Market Overview
17.2. Western Europe Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Western Europe Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.4. Western Europe Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. UK Arcalyst (Rilonacept) Market
18.1. UK Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. UK Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. UK Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Germany Arcalyst (Rilonacept) Market
19.1. Germany Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Germany Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Germany Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. France Arcalyst (Rilonacept) Market
20.1. France Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. France Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. France Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Arcalyst (Rilonacept) Market
21.1. Eastern Europe Arcalyst (Rilonacept) Market Overview
21.2. Eastern Europe Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. North America Arcalyst (Rilonacept) Market
22.1. North America Arcalyst (Rilonacept) Market Overview
22.2. North America Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. North America Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.4. North America Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. USA Arcalyst (Rilonacept) Market
23.1. USA Arcalyst (Rilonacept) Market Overview
23.2. USA Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. USA Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. USA Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.2. Canada Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. Canada Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. Canada Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. South America Arcalyst (Rilonacept) Market
25.1. South America Arcalyst (Rilonacept) Market Overview
25.2. South America Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. South America Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. South America Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. Middle East Arcalyst (Rilonacept) Market
26.1. Middle East Arcalyst (Rilonacept) Market Overview
26.2. Middle East Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. Middle East Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. Middle East Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Africa Arcalyst (Rilonacept) Market
27.1. Africa Arcalyst (Rilonacept) Market Overview
27.2. Africa Arcalyst (Rilonacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Africa Arcalyst (Rilonacept) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.4. Africa Arcalyst (Rilonacept) Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Arcalyst (Rilonacept) Market Competitive Landscape And Company Profiles
